Vaxart Inc. released clinical results on Tuesday that showed that its H1N1 tablet vaccine is just as reliable when compared to currently licensed flu vaccines.
"Our tablet flu vaccine generated broad immune responses in more than 90 percent of recipients... .” Dr. Wouter Latour, Vaxart CEO, said. “We are seeing a safety-immunogenicity profile that could compete with that of any of the currently marketed vaccines even without taking into account the convenience and logistical advantages of our room-temperature stable and user-friendly tablet. In addition our tablet vaccine could significantly increase vaccination rates currently at about 45 percent of the U.S. population.”
The data were generated in a phase 1 clinical study involving 24 healthy volunteers ages 18-49 who received either a placebo or vaccine in tablet form in a single administration. In the study, 75 percent of the subjects taking the Vaxart H1N1 tablet vaccine fully seroconverted as measured by hemagglutinin inhibition assay, a response rate equivalent to those reported for licensed injectable vaccines. None of the subjects receiving placebo (0 of 12) seroconverted.
“A tablet vaccine for flu could significantly change the way we administer vaccines," Dr. John J. Treanor, University of Rochester Medical Center chief of infectious diseases, said. “Every year, more than 100 million Americans visit their pharmacy clinic or private practitioner to receive a flu shot. In contrast, a tablet vaccine could be brought directly to the user such as in the workplace or at school, and avoids the need to worry about needles. A tablet vaccine might also be manufactured and distributed faster than current injectable vaccines, a factor that could be critical when responding to a pandemic or outbreak.